Synonyms: compound 32 [WO2019226977A1] [1]
Compound class:
Synthetic organic
Comment: Polvitolimod is classified as a toll-like receptor agonist in WHO proposed INN list 126 (January 2022). It was included in the 'COVID' section of that list. Patent mining suggests that polvitolimod is a TLR7 agonist prodrug, that was developed by Primmune Therapeutics as a potential treatment of cancer and infectious disease. In patent WO2019226977 polvitolimod's chemical structure matches that of Compound 32 [1]. Assessment of Primmune Therapeutics' pipeline indicates that polvitolimod is likely to be their clinical candidate PRTX007. If this is the correct name-to-structure association the active drug (PRX034) is likely to be compound 27 as claimed in the patent.
|
|
Download 2D Structure ![]() |
|
Canonical SMILES | Download |
Isomeric SMILES | Download |
InChI standard identifier | Download |
InChI standard key | Download |
Molecular structure representations generated using Open Babel